EMEA-000430-PIP01-08-M10

Key facts

Invented name
Xarelto
Active substance
rivaroxaban
Therapeutic area
Cardiovascular diseases
Decision number
P/0194/2017
PIP number
EMEA-000430-PIP01-08-M10
Pharmaceutical form(s)
  • Oral suspension
  • Film-coated tablet
Condition(s) / indication(s)
  • Treatment of thromboembolic events
  • Prevention of thromboembolic events
Route(s) of administration
Oral use
Contact for public enquiries
Bayer Pharma AG
Germany
Tel. +49 30300139003
E-mail: clinical-trials-contact@bayer.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating